Baxter Rolls Out Hemopatch Sealing Hemostat in Europe

Baxter introduced its Hemopatch sealing hemostat with room temperature storage at a symposium in Austria. The product is now available in Europe.

Hemopatch is an absorbable collagen pad meant for tissue sealing, dura sealing, and hemostasis. It’s effective and safe to use in open surgery and minimally invasive surgery. A registry of real-world data across Europe showed the product achieved rapid, sustainable hemostasis in many surgical specialties.

The soft, thin, pliable, flexible pad of collagen is derived from bovine dermis, coated with NHS-PEG (pentaerythritol polyethylene glycol ether tetra-succinimidyl glutarate). For differentiation, the non-coated side is marked with blue squares using a biocompatible colorant.

“More than 10 years ago, I first used Hemopatch Sealing Hemostat for experimental testing,” said General Surgeon, Prof. Dr. med. Selman Uranüs. “Since then, I have been using it in my daily practice because of its unique characteristics as a sealing hemostatic patch, especially in laparoscopic surgery. In my opinion, eliminating the need for refrigeration and increasing product shelf life are crucial improvements because it enables surgeons to have the product available in the operating room when it matters most. After application, the product shows an enhanced adhesive strength supporting us surgeons to achieve better surgical outcomes.”

“For over a decade, Hemopatch Sealing Hemostat has offered surgeons a reliable solution for tissue sealing, dura sealing, and hemostasis,” said Steve Wallace, president, Advanced Surgery at Baxter. “The product evolution to include room temperature storage is a result of close collaboration between surgeons and Baxter. Removing the need for refrigeration addresses the needs of our customers to have the product on hand in critical situations. We are proud to continue Baxter’s legacy of innovation in sealing and hemostasis.”

In February, longtime Baxter chairman, president, and CEO Joe Almeida announced his retirement. He will serve in an advisory capacity through October 31, 2025.